For how we live.
5 articles published between July 21, 2026 and October 3, 2026.
Bristol Myers Squibb's mavacamten gained an FDA efficacy supplement on 30 September. In the pivotal EXPLORER-HCM trial, 37% on the drug met the primary endpoint versus 17% on placebo.
Across 16,893 high school athletes screened over 15 years, 0.36% had T-wave inversions. Four were later found to have hypertrophic cardiomyopathy, a leading cause of sudden cardiac death in the young.
Trained on 1.7 million ECGs paired with clinicians' report text, ECG-CLIP reached the same accuracy as the best comparator with about 90% less training data — a bid at the field's labelling bottleneck.
ACACIA-HCM met both primary endpoints in symptomatic non-obstructive HCM. The gains were real but small, and one in ten patients had a reversible drop in pumping function.
A first consolidated audit of PBS and PHARMAC cardiovascular listings from 2023 to 2025 finds a widening access gap between two neighbouring countries with similar disease burdens.